{"id":273,"date":"2015-08-26T00:00:00","date_gmt":"2015-08-26T00:00:00","guid":{"rendered":"http:\/\/defranciscolaw.lawblogger.net\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/"},"modified":"2017-10-23T12:28:07","modified_gmt":"2017-10-23T16:28:07","slug":"fda-approves-the-use-of-oxycontin-for-young-patients","status":"publish","type":"post","link":"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/","title":{"rendered":"FDA approves the use of OxyContin for young patients"},"content":{"rendered":"<p>In a prior post, we highlighted the practice, as well as the dangers of off-label marketing. For those unfamiliar with the practice, off-label marketing (or use) is when doctors prescribe medications for uses that they were not intended for, or approved of by the U.S. Food and Drug Administration. Because of the long and arduous process of gaining approval through the FDA, off-label marketing and uses has become commonplace. A prime example of a successful off-label use is Viagra, which was initially intended as a drug to lower blood pressure, but is now the most famous erectile dysfunction drug in the world.<\/p>\n<p>Another example of off-label use is OxyContin for juveniles. OyxContin is a version of oxycodone, which is a powerful, opiod-based painkiller. Because OxyContin is so powerful and highly addictive, the FDA had not previously approved it for use in young people under the age of 18.\u00a0<\/p>\n<p>However, the drug\u2019s manufacturer, Purdue Pharma LP, conducted clinical trials and submitted data to FDA regarding its findings on OxyContin use in young people. Essentially, since the drug has been reformatted, it is less likely for it to be abused by being crushed or dissolved so that it may be taken through the nasal passages or intravenously. As such, <a href=\"http:\/\/www.wsj.com\/articles\/fda-approves-oxycontin-for-kids-as-young-as-11-1439577828\" target=\"_blank\">the FDA has approved it for young people<\/a>.<\/p>\n<div class=\"read_more_link\"><a href=\"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/\"  title=\"Continue Reading FDA approves the use of OxyContin for young patients\" class=\"more-link\">Continue Reading \u203a<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In a prior post, we highlighted the practice, as well as the dangers of off-label marketing. For those unfamiliar with the practice, off-label marketing (or use) is when doctors prescribe medications for uses that they were not intended for, or approved of by the U.S. Food and Drug Administration. Because of the long and arduous [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[17],"class_list":["post-273","post","type-post","status-publish","format-standard","hentry","category-failure-to-diagnose","tag-failure-to-diagnose"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA approves the use of OxyContin for young patients &#8212; Syracuse Personal Injury Law Blog &#8212; August 26, 2015<\/title>\n<meta name=\"description\" content=\"FDA approves the use of OxyContin for young patients - Failure to Diagnose - DeFrancisco &amp; Falgiatano Law Firm\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"FDA approves the use of OxyContin for young patients &#8212; Syracuse Personal Injury Law Blog &#8212; August 26, 2015\" \/>\n<meta name=\"twitter:description\" content=\"FDA approves the use of OxyContin for young patients - Failure to Diagnose - DeFrancisco &amp; Falgiatano Law Firm\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jeff DeFrancisco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA approves the use of OxyContin for young patients &#8212; Syracuse Personal Injury Law Blog &#8212; August 26, 2015","description":"FDA approves the use of OxyContin for young patients - Failure to Diagnose - DeFrancisco &amp; Falgiatano Law Firm","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/","twitter_card":"summary_large_image","twitter_title":"FDA approves the use of OxyContin for young patients &#8212; Syracuse Personal Injury Law Blog &#8212; August 26, 2015","twitter_description":"FDA approves the use of OxyContin for young patients - Failure to Diagnose - DeFrancisco &amp; Falgiatano Law Firm","twitter_misc":{"Written by":"Jeff DeFrancisco","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/","url":"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/","name":"FDA approves the use of OxyContin for young patients &#8212; Syracuse Personal Injury Law Blog &#8212; August 26, 2015","isPartOf":{"@id":"https:\/\/www.defranciscolaw.com\/blog\/#website"},"datePublished":"2015-08-26T00:00:00+00:00","dateModified":"2017-10-23T16:28:07+00:00","author":{"@id":"https:\/\/www.defranciscolaw.com\/blog\/#\/schema\/person\/798006ba40dee3a60d61603f8022a9f9"},"description":"FDA approves the use of OxyContin for young patients - Failure to Diagnose - DeFrancisco &amp; Falgiatano Law Firm","breadcrumb":{"@id":"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.defranciscolaw.com\/blog\/fda-approves-the-use-of-oxycontin-for-young-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.defranciscolaw.com\/blog\/"},{"@type":"ListItem","position":2,"name":"FDA approves the use of OxyContin for young patients"}]},{"@type":"WebSite","@id":"https:\/\/www.defranciscolaw.com\/blog\/#website","url":"https:\/\/www.defranciscolaw.com\/blog\/","name":"Syracuse Personal Injury Law Blog","description":"Published by New York Medical Malpractice Attorneys \u2014 DeFrancisco &amp; Falgiatano","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.defranciscolaw.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.defranciscolaw.com\/blog\/#\/schema\/person\/798006ba40dee3a60d61603f8022a9f9","name":"Jeff DeFrancisco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.defranciscolaw.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7f6660cf0b9e029623b52ccc2e33d1fef7eb66d590325c2b6a1fb85d5ef1e2cb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f6660cf0b9e029623b52ccc2e33d1fef7eb66d590325c2b6a1fb85d5ef1e2cb?s=96&d=mm&r=g","caption":"Jeff DeFrancisco"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/posts\/273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/comments?post=273"}],"version-history":[{"count":3,"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/posts\/273\/revisions"}],"predecessor-version":[{"id":1517,"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/posts\/273\/revisions\/1517"}],"wp:attachment":[{"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/media?parent=273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/categories?post=273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.defranciscolaw.com\/blog\/wp-json\/wp\/v2\/tags?post=273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}